Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.57 |
| ▸ | MGLL | Q99685 | 3/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | CDC25A | P30304 | 8/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431725 | 1.00 | PTGS1 (0.57) | PTGS1PTGS2MGLLFAAHCDC25A | |
| SCHEMBL13464705 | 1.00 | PTGS1 (0.57) | PTGS1PTGS2MGLLFAAHCDC25A | |
| SCHEMBL19069240 | 1.00 | PTGS1 (0.57) | PTGS1PTGS2MGLLFAAHCDC25A | |
| SCHEMBL11476165 | 0.91 | ALDH1A1 (0.50) | PTGS1PTGS2MGLLFAAHCDC25A | |
| SCHEMBL240018 | 0.91 | ALDH1A1 (0.54) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL10703043 | 0.91 | ALDH1A1 (0.54) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL15975537 | 0.91 | ALDH1A1 (0.54) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL14377618 | 0.88 | ALDH1A1 (0.56) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL11032700 | 0.86 | PTGS1 (0.48) | PTGS1PTGS2MGLLFAAHCDC25A | |
| SCHEMBL7153652 | 0.85 | MGLL (0.60) | PTGS1PTGS2MGLLFAAHCDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| CN-102382028-A | Maleimide compound, its preparation and application | UNIV ZHEJIANG TECHNOLOGY | 2012-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | PTGS1 2210/4885PTGS2 2844/4885MGLL 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.